share_log

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  12/20 17:05

Moomoo AI 已提取核心信息

MIRA Pharmaceuticals reported on December 20, 2024, that Cherry Bekaert LLP resigned as its independent registered public accounting firm on December 16. Cherry Bekaert's reports for 2022 and 2023 contained no adverse opinions, but noted material weaknesses in internal control over financial reporting. No disagreements or reportable events occurred during their tenure, except for the noted material weaknesses.On December 18, 2024, MIRA engaged Salberg & Company P.A. as its new independent auditor for the fiscal year ending December 31, 2024. This decision was recommended by the Audit Committee and approved by the Board of Directors. MIRA confirmed no prior consultations with Salberg regarding accounting principles, audit opinions, or any matters of disagreement or reportable events.
MIRA Pharmaceuticals reported on December 20, 2024, that Cherry Bekaert LLP resigned as its independent registered public accounting firm on December 16. Cherry Bekaert's reports for 2022 and 2023 contained no adverse opinions, but noted material weaknesses in internal control over financial reporting. No disagreements or reportable events occurred during their tenure, except for the noted material weaknesses.On December 18, 2024, MIRA engaged Salberg & Company P.A. as its new independent auditor for the fiscal year ending December 31, 2024. This decision was recommended by the Audit Committee and approved by the Board of Directors. MIRA confirmed no prior consultations with Salberg regarding accounting principles, audit opinions, or any matters of disagreement or reportable events.
MIRA制药公司于2024年12月20日报告称,Cherry Bekaert LLP于12月16日辞去了其独立注册公共会计师的职务。Cherry Bekaert对于2022年和2023年的报告没有不利意见,但指出在财务报告的内部控制方面存在重大缺陷。在他们任期内未发生任何分歧或可报告事件,除了所述的重大缺陷。在2024年12月18日,MIRA聘请Salberg & Company P.A.作为其2024年12月31日财政年度新的独立审计师。该决定由审计委员会推荐,并经董事会批准。MIRA确认与Salberg就会计原则、审计意见或任何分歧或可报告事件没有进行过此前的咨询。
MIRA制药公司于2024年12月20日报告称,Cherry Bekaert LLP于12月16日辞去了其独立注册公共会计师的职务。Cherry Bekaert对于2022年和2023年的报告没有不利意见,但指出在财务报告的内部控制方面存在重大缺陷。在他们任期内未发生任何分歧或可报告事件,除了所述的重大缺陷。在2024年12月18日,MIRA聘请Salberg & Company P.A.作为其2024年12月31日财政年度新的独立审计师。该决定由审计委员会推荐,并经董事会批准。MIRA确认与Salberg就会计原则、审计意见或任何分歧或可报告事件没有进行过此前的咨询。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息